MENU
+Compare
FTXH
ETF ticker: NASDAQ
AS OF
Nov 13, 04:40 PM (EDT)
Price
$31.52
Change
+$0.02 (+0.06%)
Net Assets
18.8M

FTXH stock forecast, quote, news & analysis

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index... Show more

Category: #Health
FTXH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for FTXH with price predictions
Nov 12, 2025

FTXH's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for FTXH turned positive on October 31, 2025. Looking at past instances where FTXH's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2025. You may want to consider a long position or call options on FTXH as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 232 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FTXH broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), ZOETIS (NYSE:ZTS).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF ETF is 54.17B. The market cap for tickers in the group ranges from 1.89B to 910.93B. LLY holds the highest valuation in this group at 910.93B. The lowest valued company is SRPT at 1.89B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 22%. For the same ETF, the average monthly price growth was 50%, and the average quarterly price growth was 180%. OGN experienced the highest price growth at 21%, while TGTX experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was -18%. For the same stocks of the ETF, the average monthly volume growth was 40% and the average quarterly volume growth was 35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 67
Price Growth Rating: 44
SMR Rating: 67
Profit Risk Rating: 64
Seasonality Score: 18 (-100 ... +100)
View a ticker or compare two or three
FTXH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Wheaton
Phone
N/A
Web
www.ftportfolios.com